Category Archives: patient assistance program

Is ‘what the patient pays’ the right barometer for pricing drugs?

Just a few months ago, Mylan NV got caught in a net of its own making when it raised the U.S. list price for a two-pack of its Epipen to $608, a 550 percent increase over several years. The hue…

Share

Rules of the PAP road not always clear, even to seasoned travelers

As a veteran health care journalist, I appreciate the need for biopharmas to recoup R&D costs and to operate profitably, so it’s hardly surprising to me when newly approved drugs are priced at a premium. But I’m also a consumer…

Share